Humira 40 mg/0.8 mL injection

Reason for shortage

Anticipated shortage as biosimilar transition creates temporary supply gap. AbbVie winding down branded product supply.

What to do

1. 1.
   Ensure you have adequate stock — Collect your current prescription promptly to build a small buffer before the anticipated shortage begins.
2. 2.
   Speak with your prescriber proactively — Discuss alternative options now, before the shortage occurs, so a plan is in place.
3. 3.
   Monitor TGA updates — Anticipated shortages may be resolved before they become active. Check the TGA MSI database regularly.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

• Hadlima — adalimumab biosimilar
• Amgevita — adalimumab biosimilar
• Idacio — adalimumab biosimilar